S-1/A: Farlong Holding Files IPO Amidst Going Concern Doubts

Farlong Holding Corporation, a science-driven healthcare and wellness company, filed an S-1/A for its initial public offering on Nasdaq, seeking capital to address recurring losses and fund growth initiatives.

Summary

• Farlong Holding Corporation is a science-driven healthcare and wellness company focused on proprietary dietary supplements and a DirecTCM platform.
• The company has experienced recurring losses from operations and negative cash flows since 2022, raising substantial doubt about its ability to continue as a going concern.
• Revenue for the nine months ended June 30, 2025, increased by 15.07% to approximately $0.6 million, driven by product line restructuring and new OEM customer relationships.
• Net loss for the nine months ended June 30, 2025, was approximately $1.9 million, an increase from $1.5 million in the same period of 2024.
• Gross profit decreased by 16.44% to $0.3 million for the nine months ended June 30, 2025, with gross margin falling to 55.80% from 76.84% due to lower margins on new BioPrecision products.
• Selling expenses surged by 266.16% to $0.4 million, primarily due to initial marketing efforts for the new BioPrecision product line on TikTok.
• Research and development expenses increased to $0.1 million for the nine months ended June 30, 2025, from nil in the prior year, due to clinical trials with City of Hope.
• The DirecTCM platform, launched in May 2025, had 30,000 pre-registered healthcare providers but only 75 active providers as of June 30, 2025, generating minimal subscription revenue ($376).
• The company relies heavily on a few key customers and vendors, with ZenLife accounting for 27% of revenue and Kunming Aoqun for 49% of purchases for the nine months ended June 30, 2025.
• Proceeds from the IPO are intended for general corporate purposes, R&D, marketing, infrastructure upgrades, and international expansion.
• Farlong will be a 'controlled company' post-IPO, with Karin Mei Huang and her family trusts holding significant voting power, but does not intend to rely on associated exemptions.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, negative cash flow, and a 'going concern' warning. While there are growth strategies and R&D investments, the current financial performance and high operational costs, coupled with the early and limited success of the DirecTCM platform, indicate a high-risk investment. The reliance on related-party financing and the non-statistically significant clinical trial results further temper positive sentiment, despite the potential for future growth from the IPO proceeds.

Positives

• Revenue increased by 15.07% for the nine months ended June 30, 2025, reaching $0.6 million, driven by strategic product restructuring and new OEM customer relationships.
• The BioPrecision formulation product line, launched in July 2024, generated approximately $0.3 million in revenue for the nine months ended June 30, 2025, indicating strong initial demand.
• The DirecTCM platform, launched in May 2025, has attracted approximately 30,000 pre-registered healthcare providers, with 75 active providers representing an estimated 31,500 patients encountered per month.
• The company has an experienced management team with over two decades of leadership in strategic planning, market development, and financial management.
• Farlong is investing in R&D, including three new exploratory clinical trials with City of Hope for White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl. extracts.
• Past clinical trials for Notoginseng, InnerPure, and Breviscapine showed beneficial effects on cardiovascular health, digestive support, and neuroprotection, with results published on EurekaSelect.
• The company has established a robust logistics network with three strategically located warehouses in California, Texas, and New Jersey, enabling next-day delivery to most regions in the U.S.
• Farlong has adopted a multifaceted sales strategy, diversifying distribution channels through online platforms (Amazon, TikTok, Walmart.com) and B2B wholesale to clinics and OEM partners.
• The company has self-affirmed GRAS status for several key botanical ingredients in its BioPrecision supplements, demonstrating a commitment to safety standards.

Negatives

• The company has experienced recurring losses from operations and negative cash flows since 2022, with an accumulated deficit of $5,984,259 and negative operating cash flow of $1,705,308 for the nine months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Net loss increased by 27.15% to $1.9 million for the nine months ended June 30, 2025, compared to $1.5 million in the prior year.
• Gross profit decreased by 16.44% for the nine months ended June 30, 2025, and gross margin declined significantly to 55.80% from 76.84% due to lower margins on the new BioPrecision product line.
• Selling expenses increased by 266.16% to $0.4 million for the nine months ended June 30, 2025, indicating high costs associated with marketing new products.
• The DirecTCM platform, despite 30,000 pre-registered healthcare providers, had only 75 active users (0.25%) and generated immaterial subscription revenue ($376) for the nine months ended June 30, 2025.
• The company's customer base decreased from 191 to 153 for the nine months ended June 30, 2025, due to a reduction in product mix.
• Clinical studies for products like Notoginseng, InnerPure, and Breviscapine did not demonstrate statistically significant outcomes, limiting their use for efficacy claims beyond structure/function.
• The company has identified material weaknesses in internal control over financial reporting, including a lack of formal risk assessment policies and IT-related deficiencies.
• Heavy reliance on a small number of customers and vendors poses a significant risk; for example, one customer accounted for 27% of revenue and one vendor for 49% of purchases for the nine months ended June 30, 2025.
• The company is highly vulnerable to U.S. tariffs and trade disputes with China, as all supplement products are produced by contract manufacturers located there, potentially increasing costs and harming profitability.

Risks

• Significant accumulated deficits and negative cash flows raise substantial doubt about the ability to continue as a going concern.
• Need for additional capital, which may not be available on commercially acceptable terms, if at all, leading to potential dilution or business curtailment.
• Operating results may vary considerably, making future performance challenging to forecast and potentially causing results to fall short of expectations.
• Failure to maintain high-quality standards for products and services could harm business and reputation, leading to recalls, negative publicity, and customer loss.
• Reliance on a small number of customers and vendors means the loss of any material party could adversely affect operations.
• Customer demand is difficult to forecast accurately, potentially leading to an inability to match planning and spending decisions.
• Significant revenue derived from Amazon and TikTok (15% and 19% respectively for 9 months ended June 30, 2025) makes the business vulnerable to platform policy changes or restrictions.
• Increases in ingredient costs, long lead times, and supply shortages could disrupt the supply chain and negatively impact financial results.
• Allocation of limited resources to particular products or services may lead to missed opportunities for more profitable ventures.
• Risk of inventory spoliation due to definitive shelf-lives, potentially leading to write-offs and significant charges.
• Failure to renew current leases or locate desirable alternatives for facilities could materially and adversely affect the business.
• Potential future need for licenses for third-party technology that may be unavailable or offered on commercially unreasonable terms.
• High costs and uncertainty of litigation may prevent enforcement of intellectual property rights against third parties.
• Struggles to partner for technological advancements and new products/services could hinder competitiveness.
• Use of open-source software could subject proprietary software to general release, hinder product sales, and expose the company to litigation.
• Exposure to risks associated with credit card and other online payment chargebacks and fraud.
• Risks associated with the return policy and warranty if actual returns or claims exceed estimates.
• Clinical studies present inherent risks, and past results have not demonstrated statistical significance, potentially diminishing consumer confidence.
• Dependence on brands (Dr. Herbal Well, Best Doctor Formula) means any failure to maintain, protect, or enhance them could adversely affect the business.
• Sourcing ingredients from foreign suppliers (primarily China) exposes the company to risks related to international trade, importation, tariffs, and supply chain disruptions.
• Substantial portion of sales relies on distributors and health professionals, over whom the company has limited control, posing risks if relationships deteriorate or compliance fails.
• Reliance on independent third-party transportation providers for all product shipments, subject to increased costs and potential delivery delays.
• Insurance does not fully cover all operational risks, and changes in cost or availability could increase expenses or decrease coverage.
• Disruptions in data and information systems, including cybersecurity risks, could harm reputation and business operations.
• Reliance on third-party cloud infrastructure providers (e.g., Amazon Web Services) for computing, storage, and processing services, with potential for disruptions or increased costs.
• Future acquisitions may have an adverse effect on business management and could cause dilution to stockholders.
• High vulnerability to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations due to reliance on Chinese contract manufacturers.
• Intense competition in the herbal supplement industry from existing and new entrants with greater resources.
• Global economic conditions (inflation, recession, tariffs, interest rates) could materially and adversely affect business, financial condition, and growth.
• Risk of intellectual property litigation, including claims of infringement against the company.
• Subject to numerous laws and regulations applicable to the herbal supplement industry (FDA, FTC, HIPAA, state laws), with potential for fines, recalls, or operational restrictions for non-compliance.
• Changes in FDA and other regulatory agency policies, or disagreements over product classifications, could delay or increase costs.
• Economic downturns or changes in consumer preferences could limit demand for products.
• Marketing activities are subject to strict governmental regulation, limiting ability to promote products.
• Failure to comply with federal, state, and foreign laws relating to privacy, data protection, and consumer protection could result in significant liability and harm reputation.
• Potential for allegations, harassment, or other detrimental conduct by third parties, harming reputation and market share.
• No public market for common stock prior to this offering, and inability to resell at or above IPO price.
• Market price of common stock may be volatile or decline regardless of operating performance.
• Immediate and substantial dilution in net tangible book value for common stock purchased in this offering.
• Failure to implement and maintain effective internal controls or remediate identified material weaknesses could affect reporting accuracy and investor confidence.
• Substantial increased costs as a result of being a public company.
• Inability to continue to satisfy Nasdaq listing requirements could lead to delisting.
• Management has broad discretion over use of IPO funds, which may not enhance results or stock price.
• As a controlled company, the company could elect to rely on corporate governance exemptions, adversely affecting public stockholders.
• As an emerging growth company and smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• Nasdaq may apply additional and more stringent listing criteria due to small public offering and large insider holdings.
• Authorized preferred stock can be designated by the board without stockholder approval, potentially causing substantial dilution or affecting voting rights.
• Anti-takeover provisions in corporate documents and Nevada law might discourage, delay, or prevent a change in control.
• Sale of a significant number of shares by existing stockholders after lock-up expiration could cause the market price to drop significantly.

Future Outlook

The company intends to use IPO net proceeds for general corporate purposes, including working capital, R&D, marketing, infrastructure upgrades, and international expansion to Asian and European markets. It plans to continue investing in its DirecTCM platform, refining supplement recommendation methods, and expanding its product lines, particularly those with self-affirmed GRAS conclusions. The company expects to require approximately $3 million of additional working capital to scale marketing programs for profitability and $2 million for a full commercial rollout of international expansion.

Management Comments

• Our regulatory objective is limited to marketing our formulations in the United States as dietary supplements, for which FDA approval is neither required nor available.
• We believe the following strengths are essential for our success and differentiate us from our competitors: Proprietary technology and intellectual property; Established brand; Large and growing customer base; Experienced management team with strong financial and operational expertise; and Innovative culture, and research and development (R&D) capabilities.
• We intend to develop our business and strengthen our brand loyalty by implementing the following strategies: Expansion plans on DirecTCM platform and products; Investment in technology and R&D; and Plans for growing our business.
• Our management has determined that these conditions (recurring losses and negative cash flows) raise substantial doubt about our ability to continue as a going concern.
• We can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to us, if at all.
• Our management will have significant flexibility and discretion in applying the net proceeds from this offering.
• We believe that our ability to compete depends upon many factors both within and beyond our control, including our marketing efforts, product flexibility, quality and price, brand strength, customer satisfaction, and ability to comply with regulations.
• We believe Mr. Morgan is well qualified to serve as our independent director because of Mr. Morgan's strong background in financial management and leadership.
• Ms. Chang's proven track record in structuring and managing complex financings, familiarity with credit and risk-control frameworks, and knowledge of banking-industry regulations will provide valuable insight into capital-raising strategies, treasury management, and enterprise-risk oversight, making her a highly qualified addition to the board.
• Mr. Zhou's record of establishing finance infrastructures for emerging public companies, capital-raising and asset-management expertise, and familiarity with SEC and Nasdaq requirements will add critical depth to our audit-committee work, capital-allocation deliberations, and strategic initiatives, making him a strong fit for service as an independent director.

Industry Context

The global dietary supplement market is valued at $74.3 billion in 2024 and is projected to reach $170.1 billion by 2034, growing at a CAGR of 9.5%. The holistic herbal supplement market is also expanding, from $216 billion in 2022 to an expected $421 billion by 2032 (CAGR of 6.87%). The U.S. market, a leading supplier, is expected to grow at a CAGR of 7.2% from 2024 to 2034, driven by increasing health awareness and demand for plant-based products. Farlong operates in a highly competitive industry with many larger, more established competitors, and its strategy of combining traditional herbal knowledge with scientific validation and personalized health approaches aligns with consumer preferences for natural and science-backed solutions. However, the company's current financial performance and reliance on a few customers/vendors present challenges in this growing but competitive landscape.

Comparison to Industry Standards

• The company's clinical studies for Notoginseng, InnerPure, and Breviscapine were exploratory and did not demonstrate statistically significant outcomes, which is a notable deviation from the rigorous efficacy standards often sought in the broader pharmaceutical or advanced nutraceutical industry, where statistical significance is a key indicator of product effectiveness.
• Farlong's self-affirmed GRAS status for certain ingredients, while compliant with FDA guidance for dietary supplements, is not equivalent to FDA approval, which is a higher standard for drugs and some food additives. This positions its products differently from those that might pursue drug-like regulatory pathways.
• The company faces competition from larger, more established players like Throne HealthTech, Nestle Health Science, and Metagenics in the nutritional supplement market, and Fullscript in online ordering. These competitors often possess greater financial, technological, and marketing resources, as well as larger customer bases and more efficient fulfillment infrastructures, which Farlong currently lacks.
• Farlong's reliance on a small number of customers and vendors (e.g., ZenLife for 27% of revenue, Kunming Aoqun for 49% of purchases) is a concentration risk that is generally higher than what is considered ideal for diversified, stable businesses in the industry.
• The company's recurring losses and 'going concern' warning indicate financial instability that is below industry standards for a healthy, growing enterprise, especially one seeking public investment.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed against Longstar on June 20, 2024, by a former employee alleging $1,222,000 in unpaid compensation from 2016 to 2023. Longstar's legal counsel believes the likelihood of liability is remote, and no loss contingency has been recorded.

Related Party Transactions

• Long-term loans from Karin Mei Huang (stockholder/trustee): $1,000,000 loan dated September 15, 2024, at 9.5% interest, maturing September 15, 2029. An additional $1,600,000 loan dated March 25, 2025, at 9.5% interest, maturing March 25, 2030. Interest payments on the first loan were deferred from April 1, 2025, through March 31, 2026.
• Accrued loan interest to Karin Mei Huang: $67,593 as of June 30, 2025.
• Purchases from Kunming Aoqun Bio-Tech Co., Ltd. (related party due to Lihua Zeng, family member of Lipin Zeng, serving as director): $131,148 for the nine months ended June 30, 2025, and $815,172 for the fiscal year ended September 30, 2024. Accounts payable to Kunming Aoqun were $781,668 as of June 30, 2025.
• Purchases from Yunnan Panlong Yunhai Pharmaceutical Co., Ltd. (related party due to Lihua Zeng owning 30%): Accounts payable to Yunnan Panlong were $60,441 as of June 30, 2025.
• Rent expenses paid to Longstar Healthpro Manufacturing Inc. (majority owned by Xinjiang Lixing, a former stockholder owned by Lihua Zeng): $117,000 for the nine months ended June 30, 2025, and $156,000 for the fiscal year ended September 30, 2024. Rent deposit of $19,500 held by this entity.
• On July 28, 2025, purchased inventories from Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd (a wholly owned subsidiary of Yunnan Panlong) for $23,390.
• Share exchange on December 27, 2023, where Karin Mei Huang exchanged 100% of Longstar's equity for 40,000,000 shares of Farlong's common stock, making Longstar a wholly-owned subsidiary.
• Asset transfer on December 31, 2022, from Longstar to Xinjiang Lixing (former majority shareholder under common control of Karin Mei Huang), involving real property, ACA common stock, and other assets totaling $1,563,493.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the IPO. Existing shareholders (KML Family Trust and KMA Trust, controlled by Karin Mei Huang) will retain significant voting power, making the company a 'controlled company.' The 'going concern' warning poses a significant risk of loss of investment.
• Employees: The company is expanding its workforce and establishing distinct departments, which could lead to new opportunities. However, the 'going concern' risk could impact job security if additional capital is not secured.
• Customers: May benefit from expanded product lines (BioPrecision), enhanced DirecTCM platform services, and improved logistics for faster delivery. However, potential price increases due to tariffs or supply chain disruptions could negatively impact them.
• Suppliers: The company's reliance on a few key suppliers, particularly those in China, exposes them to risks from trade disputes and potential changes in sourcing strategies. Related-party suppliers benefit from ongoing purchase agreements and loans.
• Creditors: Related-party creditors (Karin Mei Huang) have provided significant loans, indicating a reliance on internal financing. The 'going concern' risk could impact the recoverability of these debts if the company fails to achieve profitability.

Next Steps

• Proceed with the Initial Public Offering (IPO) and listing on the Nasdaq Capital Market under the symbol AFA, contingent on Nasdaq's final approval.
• Utilize IPO net proceeds for general corporate purposes, including working capital, R&D, marketing, infrastructure upgrades, and international expansion.
• Continue investment in the DirecTCM platform, refining supplement recommendation methods and expanding its knowledge library.
• Advance the three ongoing exploratory clinical trials with City of Hope for White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl. extracts.
• Implement additional remedial measures to address identified material weaknesses in internal control over financial reporting, including hiring qualified accounting personnel and establishing a financial and system control framework.
• Scale marketing programs for profitability, requiring approximately $3 million of additional working capital.
• Pursue full commercial rollout of international expansion to Asian and European markets, requiring approximately $2 million of additional capital.
• The Audit Committee will review related party transactions to determine fairness to the company and stockholders.
• The company plans to implement a policy prohibiting hedging transactions by employees in the future.

Key Dates

Recommendation

Farlong Holding Corporation presents a high-risk investment profile. The company has a documented history of recurring losses and negative cash flows, leading to a 'substantial doubt about our ability to continue as a going concern.' This fundamental financial instability is a critical red flag. While the IPO aims to raise capital, the company's reliance on related-party financing, significant increases in selling and R&D expenses without clear paths to profitability, and the very low active user engagement on its new DirecTCM platform are concerning. Furthermore, the clinical trials, while a positive for R&D, have not yielded statistically significant results, limiting their commercial impact. The heavy dependence on a few customers and Chinese manufacturers exposes the company to substantial operational and geopolitical risks. Given the severe financial challenges, high operational risks, and lack of clear, proven market traction for its new initiatives, a seasoned investor would likely view this as a 'strong sell' due to the significant downside potential and uncertainty surrounding its long-term viability.

Keywords

Herbal Supplements, Dietary Supplements, Traditional Chinese Medicine, TCM, BioPrecision, DirecTCM, IPO, SEC Filing, S-1/A, Healthcare Wellness, Contract Manufacturing, e-commerce, Nasdaq Listing, Going Concern, Clinical Trials, GRAS Status, Risk Factors, U.S.-China Trade, Corporate Governance, Capital Raise